20.71
0.60 (3.01%)
| Penutupan Terdahulu | 20.10 |
| Buka | 20.21 |
| Jumlah Dagangan | 929,588 |
| Purata Dagangan (3B) | 8,446,373 |
| Modal Pasaran | 14,400,153,600 |
| Harga / Jualan (P/S) | 714.40 |
| Harga / Buku (P/B) | 3.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Feb 2026 |
| Margin Operasi (TTM) | -4,823.84% |
| EPS Cair (TTM) | -0.750 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.93% |
| Nisbah Semasa (MRQ) | 33.47 |
| Aliran Tunai Operasi (OCF TTM) | -839.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -375.20 M |
| Pulangan Atas Aset (ROA TTM) | -10.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Roivant Sciences Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | -1.00 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 30.31% |
| % Dimiliki oleh Institusi | 83.49% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 26.00 (Citigroup, 25.57%) | Beli |
| Median | 20.50 (-0.99%) | |
| Rendah | 16.50 (B of A Securities, -20.31%) | Pegang |
| Purata | 21.19 (2.34%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 15.82 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 11 Nov 2025 | 26.00 (25.57%) | Beli | 20.90 |
| 29 Oct 2025 | 25.00 (20.74%) | Beli | 18.76 | |
| B of A Securities | 18 Sep 2025 | 16.50 (-20.31%) | Pegang | 15.09 |
| Goldman Sachs | 18 Sep 2025 | 24.00 (15.91%) | Beli | 15.09 |
| Guggenheim | 18 Sep 2025 | 21.00 (1.42%) | Beli | 15.09 |
| HC Wainwright & Co. | 18 Sep 2025 | 20.00 (-3.40%) | Beli | 15.09 |
| JP Morgan | 18 Sep 2025 | 20.00 (-3.40%) | Beli | 15.09 |
| Jefferies | 18 Sep 2025 | 20.00 (-3.40%) | Beli | 15.09 |
| Leerink Partners | 18 Sep 2025 | 22.00 (6.25%) | Beli | 15.09 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |